Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-751 in Advanced, Androgen-Independent Prostate Cancer
NCT00471718Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jan 2004
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abt-751 in prostate cancer (PCa), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Maximum Tolerated Dose up to 4 weeks and Prostate Specific Antigen Response. Started Jan 2004; status: terminated.
02
Drugs
abt-751
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00471718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471718.